Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 30, 2015 - Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card Read
- Dec. 29, 2015 - Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card Read
- Dec. 23, 2015 - ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card Read
- Dec. 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II trial of PB272 in HER2 Mutation Positive Cancer Patients Read
- Dec. 16, 2015 - Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea Read
- Dec. 11, 2015 - Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET trial) at the 2015 San Antonio Breast Cancer Symposium Read
- Dec. 10, 2015 - Puma Biotechnology Presents Interim Results of Phase II trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium Read
- Dec. 10, 2015 - Puma Biotechnology Announces Results of Phase II trial of PB272 in Neoadjuvant treatment of HER2-Positive Locally Advanced Breast Cancer Read
- Nov. 30, 2015 - Puma Biotechnology Provides Update from Meeting with European Medicines Agency Read
- Nov. 13, 2015 - Puma Biotechnology to Present Data at the San Antonio Breast Cancer Symposium (SABCS) Read
- Nov. 9, 2015 - Puma Biotechnology Reports Third Quarter 2015 Financial Results Read
- Nov. 3, 2015 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
- Sept. 26, 2015 - Puma Biotechnology Announces Presentation of Phase III trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients Read
- Sept. 10, 2015 - Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation Read
- Aug. 10, 2015 - Puma Biotechnology Reports Second Quarter 2015 Financial Results Read
- June 4, 2015 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read
- June 1, 2015 - Puma Biotechnology Announces Phase III trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET trial) Demonstrates Statistically Significant Improvement in Disease Free Survival Read
- May 27, 2015 - Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference Read
- May 13, 2015 - Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Read
- May 12, 2015 - Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference Read
- May 11, 2015 - Puma Biotechnology Reports First Quarter 2015 Financial Results Read
- May 6, 2015 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference Read
- April 30, 2015 - Puma Biotechnology to Present at Deutsche Bank Health Care Conference Read
- April 14, 2015 - Puma Biotechnology Expands Cohort in Phase II trial of PB272 in HER2 Mutation Positive Cancer Patients Read
- March 10, 2015 - Puma Biotechnology Initiates Phase II trial of PB272 in Early Stage HER2-Positive Breast Cancer Read
- March 2, 2015 - Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results Read
- Feb. 24, 2015 - Puma Biotechnology to Present at Cowen Health Care Conference Read
- Feb. 18, 2015 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Read
- Feb. 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference Read
- Jan. 27, 2015 - Puma Biotechnology Closes $218 Million Public Offering of Common Stock Read
- Jan. 22, 2015 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares Read
- Jan. 21, 2015 - Puma Biotechnology Prices Public Offering of Common Stock Read
- Jan. 20, 2015 - Puma Biotechnology Announces Proposed Public Offering Read
- Jan. 5, 2015 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read